Oslo, Norway, 1 February 2018

Malene Brondberg, VP IR & CC has been granted 20,000 performance share units
("PSUs") in connection with her appointment. For further information about the
PSUs and the related warrants see the company's stock exchange announcement on
29 January 2018. Following the allocation, Malene Brondberg holds 20 000 PSUs, 0
options and 0 shares in Nordic Nanovector.

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC)
designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 20 billion by 2024. The company aims to rapidly
develop Betalutin®, alone and in combination with other therapies, for the
treatment of major types of NHL, targeting first regulatory submission in
relapsed/refractory follicular lymphoma in 2019. Nordic Nanovector intends to
retain marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. The company is also advancing a pipeline of ARCs and
other immunotherapies for multiple cancer indications. Further information about
the company can be found at www.nordicnanovector.com

This information is subject to duty of disclosure pursuant to Section 4-2 of the
Norwegian Securities Trading Act

